Updated NICE guidelines announced for VEGF treatment of "wet" age related macular degeneration.-Bayer + Regeneron
Updated guidelines from the National Institute for Health and Care Excellence (NICE) state that intravitreal anti-vascular endothelial growth factor (VEGF) treatment should be offered for late AMD (wet active) for eyes with visual acuity within a specified range. Lucentis (ranibizumab) or Eylea (aflibercept) can be considered a treatment option if: the best-corrected visual acuity is between 6/12 and 6/96; there is no permanent structural damage to the central fovea; the lesion size is less than or equal to 12 disc areas in greatest linear dimension; and there is evidence of recent presumed disease progression. Also, in both cases NICE�s endorsement is contingent on the continued provision of a patient access scheme, which reduced the cost to these drugs to the NHS.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins